Clin Osteol 2004; 9(1): 6-10

Bisphosphonates in the management of metabolic skeletal disorders in adultsArticles

V. Vyskočil

Bisphosphonates play a leading role in the treatment of several metabolic bone diseases. Bisphosphonates are currently being used to succesfully treat postmenopausal, senile, male and glucocorticoid-induced osteoporosis, Paget's disease of bone, osteolytic bone disease of malignancy and post-trans­ plant bone disease. Bisphosphonates are considered as prom an overview on current therapeutic use of bisphosphonates.

Keywords: bisphosphonates, osteoporosis.

Published: June 11, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vyskočil V. Bisphosphonates in the management of metabolic skeletal disorders in adults. Osteologický bulletin. 2004;9(1):6-10.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Delmas 335:1836.
    2. Fleisch H, Russel RGG, Bisaz S, et al. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitr cification in vivo. Eur J Clin Invest 1970;1:12-18. Go to original source...
    3. Fleisch H. Bisphosphonates in Bone Diseases. Third Edition. New Yo henon Publishing Group, 1997:32-38,39-57,58-63,69-85,117-144,112-116.
    4. Papapoulos SE. Bisphosphonates: Structure-activit spective. Medicina (B Aires) 1997;57(Suppl.1):61-64.
    5. Shane E, Addesso V, Namerow PB, et al. Alendronate versus Calcitri vention of Bone Loss after Cardiac Transplantation N Engl J Med 2004; 350:767-776. Go to original source...
    6. Schmidt A, Rutldge SJ, Endo A, et al. Protein-tyrosine phosphatase aktivity regu­ lates osteoclast formation Sci USA 1996;93:3068-3073. Go to original source...
    7. Mackay FJ, Wilton LV, Jfearce GL, et al. United Kingdom experienc ronate and oesophageal reactions. Br J Gen Pract 1998;48:1161-1162.
    8. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and tr ment of glucocorticoid-induced osteoporosis. NEJM 1998;339:292-299. Go to original source...
    9. Ravn P, Christensen JO, Baumann M, et al. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction ofbone mass changes during treatment. Bone 1998;22:559-564. Go to original source...
    10. Stock JL, Bell NH, Chesnut CH, et al. Increments in bone mineral density of lumbar spine and hip and suppression of bone turnover are maintained after dis­ continuation of alendronate in postmenopausal women. Am J Med 1997;103:291-297. Go to original source...
    11. Harris ST, Watts NB, Genant HK, et al. For the Vertebral Efficacy With Ris nate Therapy (VERT) Study Group: Effects of Risedronate Treatment on Verteb­ ral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis. JAMA, 1999;282:1344-1352. Go to original source...
    12. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk. Arch Intern Med 1997;157:2617-2624. Go to original source...
    13. Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients osteoporosis. J Clin Invest 1997;100:1475-1480. Go to original source...
    14. McClung MR, Geusens P, Miller PD, et al. Hip Intervention Program Study Group: Effect of risedronate on the risk of hip fractu tervention Program Study Group. NEJM 2001;344:333-340. Go to original source...
    15. Rago L. Ensuring access to drug products that are of acceptable quality lot Procurement, Quality and Sourcing (pre-qualification) project WHO/EDM Technical briefing seminar, 2 October 2002, Geneva. WHO Web site http://www.who.int/medicines/organization/
    16. Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous in tions of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103:298-307. Go to original source...
    17. Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established osteoporo a systematic review and cost-utility analysis. Health Technol Assess 2002;6(29). Go to original source...
    18. Gonnelli S, Rottoli P, Capollaro C, et al. Prevention of corticosteroid-induced teoporosis with alendronate in sarcoid patients. Calcif Tiss Int 1997;61:382-385. Go to original source...
    19. Brunner K, Fleisch H, Senn H. Biphosphonates and Tumor Osteolysis, Recent Re­ sult in cancer research 1989;116. Go to original source...
    20. Eastel R, Boyle IT, Compston J, et al. Management of male osteoporosis: report of the UK Consensus Group. Q J Med 1998;91:71-92. Go to original source...
    21. Adami S, Zamberlan A, Mian M, et al. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparat­ hyroidism and J^get's disease of bone. Bone Miner 1994;25:75-82. Go to original source...
    22. Hilner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology Guideline on the Role of Biphosphonates in Breast Cancer. J Clin Onc 2000;18:1378-1391. Go to original source...
    23. Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellu­ lar matrices. Cancer Res 1997;57:3890-3894.
    24. Kanis JA, Powles T, Paterson AHG, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996;19:663-667. Go to original source...
    25. Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. Editorial. NEJM 1998;339:398 400. Go to original source...
    26. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases breast cancer patients treated with intravenous pamidronate: Results from a multi­ national randomized controlled trial. J Clin Oncol 1996;14:2552-2559. Go to original source...
    27. Horowitz M, Wishart JM, Need AG, et al. Primary hyperparathyroidism. Clin Geriatr Med 1994;10:757-775. Go to original source...
    28. Lipton A, Berenson JR, Levy E, et al. Phase II study of the biphosphonate zoled­ ronate in patients with osteolytic lesions. Presented at 1999 Second Int Conf Can­ cer Induced Dis, Davos, Switzerland, March 27-29,1999.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.